EPICS: Global Perspectives in CRC in 2023 and Beyond

Latest therapeutic developments in GI cancer treatment and implications on individualized clinical decision-making. How will emerging data shape future treatment paradigms?

January 21, 2023
Purchase Report

FACULTY CHAIR

Alan Venook, MD, FASCO

Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

Faculty Members

Thierry André, MD
Sorbonne Université, Paris, France

Dirk Arnold, MD, PhD
University of Hamburg, Germany

Andrea Cercek, MD
Memorial Sloan Kettering Cancer Center , New York, NY, USA

Kristen Ciombor, MD
Vanderbilt University Medical Center, Nashville, TN, USA

Aparna Parikh, MD
Harvard Medical School, Boston, MA, USA

 

Sample Report

Start discovering the insights

View Report

REPORT TOPICS INCLUDE

  • Current Treatment Paradigms for Early-Stage CRC (MSS/pMMR)
  • Current Treatment Paradigms for Metastatic CRC
  • The Evolving Role of Immunotherapy in CRC
  • Currently Available Targeted Therapies for CRC
  • Emerging Therapies and Novel Investigational Approaches for CRC
  • Current and Evolving Biomarkers in CRC

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.